BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31091046)

  • 1. [Matrix metalloproteinases-1, -13 and their tissue inhibitor-1 in endocrine ophthalmopathy].
    Taskina ES; Kharintseva SV
    Probl Endokrinol (Mosk); 2019 May; 65(1):10-18. PubMed ID: 31091046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
    Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
    Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
    Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
    Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and functional insights into the interaction of sulfated glycosaminoglycans with tissue inhibitor of metalloproteinase-3 - A possible regulatory role on extracellular matrix homeostasis.
    Rother S; Samsonov SA; Hofmann T; Blaszkiewicz J; Köhling S; Moeller S; Schnabelrauch M; Rademann J; Kalkhof S; von Bergen M; Pisabarro MT; Scharnweber D; Hintze V
    Acta Biomater; 2016 Nov; 45():143-154. PubMed ID: 27545813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
    Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
    Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Age-related dynamics of the contents of matrix metalloproteinases (MMP-1, -2, -3, -9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -4) in blood plasma of residents of the European part of the Arctic zone of the Russian Federation.].
    Kim LB; Russkih GS; Putyatina AN; Tsypysheva OB
    Adv Gerontol; 2018; 31(2):223-230. PubMed ID: 30080329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
    Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
    Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue.
    Kubota T; Itagaki M; Hoshino C; Nagata M; Morozumi T; Kobayashi T; Takagi R; Yoshie H
    J Periodontol; 2008 Jan; 79(1):166-73. PubMed ID: 18166107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level.
    Komosinska-Vassev K; Olczyk P; Winsz-Szczotka K; Kuznik-Trocha K; Klimek K; Olczyk K
    Gerontology; 2011; 57(1):44-52. PubMed ID: 20215736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients.
    Ninomiya T; Yoon S; Nagano H; Kumon Y; Seo Y; Kasuga M; Yano Y; Nakaji M; Hayashi Y
    Intervirology; 2001; 44(4):227-31. PubMed ID: 11509885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metalloproteinases and Their Inhibitors in Patients with Inguinal Hernia.
    Isik A; Gursul C; Peker K; Aydın M; Fırat D; Yılmaz İ
    World J Surg; 2017 May; 41(5):1259-1266. PubMed ID: 28050662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity.
    Wiercinska-Drapalo A; Jaroszewicz J; Flisiak R; Prokopowicz D
    World J Gastroenterol; 2003 Dec; 9(12):2843-5. PubMed ID: 14669348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.